klacid i.v.500 mg pulveris infūziju šķīduma koncentrāta pagatavošanai
viatris sia, latvia - klaritromicīns - pulveris infūziju šķīduma koncentrāta pagatavošanai - 500 mg
clarithromycin unifarma 500 mg pulveris infūziju šķīduma pagatavošanai
unifarma, sia, latvia - klaritromicīns - pulveris infūziju šķīduma pagatavošanai - 500 mg
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistiskā fibroze - other respiratory system products - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
aubagio
sanofi winthrop industrie - teriflunomīds - multiplā skleroze - selective immunosuppressants - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
clarithromycin grindeks 500 mg apvalkotās tabletes
grindeks, as, latvia - klaritromicīns - apvalkotā tablete - 500 mg
clarithromycin grindeks 250 mg apvalkotās tabletes
grindeks, as, latvia - klaritromicīns - apvalkotā tablete - 250 mg
klatex 500 mg ilgstošās darbības tabletes
teva pharma b.v., netherlands - klaritromicīns - ilgstošās darbības tabletes - 500 mg
hepcludex
gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - pretvīrusu līdzekļi sistēmiskai lietošanai - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
teriflunomide accord
accord healthcare s.l.u. - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - immunosuppressants, selektīvi immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).